Key Points
- Teva CAO Amir Weiss sold 12,300 shares on Dec. 16 at an average price of $30.20 for a total of $371,460, leaving him with 5,650 shares — a 68.52% reduction in his ownership.
- Wall Street sentiment is broadly positive with a consensus "Buy" rating and an average price target of $31.13; notable moves include JPMorgan raising its target to $35 and Goldman Sachs to $31.
- TEVA shares recently opened at $30.28 (12-month range $12.47–$30.44) and the company has a market cap of about $34.7 billion and a trailing P/E of 50.47.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) CAO Amir Weiss sold 12,300 shares of the business's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Teva Pharmaceutical Industries Trading Up 0.7%
Shares of TEVA opened at $30.28 on Friday. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $30.44. The stock has a market cap of $34.73 billion, a PE ratio of 50.47, a P/E/G ratio of 1.79 and a beta of 0.67. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The business's 50-day moving average price is $24.23 and its 200-day moving average price is $19.95.
Institutional Trading of Teva Pharmaceutical Industries
Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. Hudson Bay Capital Management LP increased its stake in Teva Pharmaceutical Industries by 87.5% in the 3rd quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company's stock worth $4,545,000 after purchasing an additional 105,000 shares during the period. Steadtrust LLC grew its holdings in shares of Teva Pharmaceutical Industries by 58.1% in the third quarter. Steadtrust LLC now owns 37,300 shares of the company's stock worth $753,000 after purchasing an additional 13,700 shares during the last quarter. Cantor Fitzgerald L. P. purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $1,392,000. CIBC Private Wealth Group LLC raised its holdings in Teva Pharmaceutical Industries by 15.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company's stock valued at $81,000 after buying an additional 540 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth $234,000. Hedge funds and other institutional investors own 54.05% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 13th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Tuesday. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a "buy" rating in a research report on Monday, December 8th. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Buy" and an average price target of $31.13.
Read Our Latest Stock Analysis on Teva Pharmaceutical Industries
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
